Zhejiang ChiMin Pharmaceutical Co Ltd (603222.SS)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Zhejiang Chimin Pharmaceutical To Buy 60 Pct Stake In Hospital For 126 Mln Yuan
- BRIEF-Zhejiang Chimin Pharmaceutical's Share Trade To Halt Pending Announcement Related To Acquisition
- China stocks reverse losses, end higher as banks jump
- Blue chips lead China stocks lower as investors book profits
- China stocks fall as investors take profits on blue-chip rally; HK flat